Diana L. Moss

Diana Moss became the President of the American Antitrust Institute in January 2015. Since joining AAI in 2001, Dr. Moss has developed and expanded AAI’s advocacy channels and strategies, and strengthened communications with public and private enforcers, Congress, other advocacy groups, and the media. Her work spans both antitrust and regulation, with industry expertise in other areas.  From 1995 to 2001, Dr. Moss served in the Office of Economic Policy and Office of Markets, Tariffs, and Rates at the Federal Energy Regulatory Commission. There, she coordinated the agency’s economic analysis for electricity mergers and contributed to the development of the landmark open access rules. From 1989 to 1995, she consulted in private practice in the areas of regulation and antitrust. Dr. Moss is also Adjunct Faculty in the Department of Economics at the University of Colorado at Boulder.

Dr. Moss has spoken widely on various topics involving competition policy and enforcement, testified before Congress, appeared before state and federal regulatory commissions, at industry and academic conferences, and made numerous radio and television appearances. She has published articles in numerous economic and legal journals as well.

Dr. Moss was named to the GCR’s Women in Antitrust in 2016 and again in 2021.  In 2021, Dr. Moss was inducted into the American Bar Association Antitrust Law Section’s Hall of Fame-inism.  She holds a M.A. degree from the University of Denver and a Ph.D. from the Colorado School of Mines.

The United States Needs a National Standards Strategy

By Richard Taffet and Chris Borges Competition among nations for technological and economic leadership is intense, especially between the United States and the People’s Republic of China (PRC). The PRC has followed a decades-long, targeted strategy focused on leadership in critical and emerging technologies (CETs), and, according to some, it has
Read More

How Most-Favored Nation Policy Could Undermine U.S. Leadership

By Dr. Anne Pritchett The United States is the global leader in biopharmaceutical innovation. This leadership is built on the pillars of strong intellectual property protection, substantial investment in research and development (R&D), and a robust innovation ecosystem. These factors, combined with a market-based system that supports competitive drug pricing, encourage innovation and
Read More

U.S. Patenting Abroad — A Quiet Trade Advantage

By Chris Borges   Although patents are territorial, meaning they are limited to the jurisdiction in which they are granted, the networks spanning innovation and commerce are global. U.S. inventors routinely seek patent protection in markets abroad to safeguard their innovations, facilitate exports, and access new customers. By requiring member states
Read More